The Safety and Efficacy of TLL-018 in Active Rheumatoid A... | NCT05133297

NCT05133297

Protocol Section

Identification Module

Results Section

No data available

No data is available for this block.

Annotation Section

No data available

No data is available for this block.

Document Section

No data available

No data is available for this block.

Derived Section

Miscellaneous Info Module

Status Module

Label	Type	Description	Intervention Names
Sequence 1	Experimental	TLL018 tablets, 1piece,BID	Drug: TLL-018
Sequence 2	Experimental	TLL018 tablets, 2pieces, BID	Drug: TLL-018
Sequence 3	Experimental	TLL018 tablets, 3pieces, BID	Drug: TLL-018
Sequence 4	Active Comparator	TOFA tablets, 1pieces, BID	Drug: Tofacitinib

Name	Type	Description	Arm Group Labels	Other Names
TLL-018	Drug	Oral tablets administered at dose1 BID daily for 24 weeks.	Sequence 1

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
Number of Participants American College of Rheumatology 50% (ACR50) Response at Week 12	A participant was a responder if the following 3 criteria for improvement from baseline were met: ≥50% improvement in 68-tender joint count; ≥50% improvement in 66-swollen joint count; and ≥50% improvement in at least 3 of the 5 following parameters:	Week 12

Secondary Outcomes

Measure	Description	Time Frame
Number of Participants American College of Rheumatology 20% (ACR20) Response	ACR20 response: greater than or equal to (>=) 20 percent (%) improvement in painful and tender joint count; >= 20% improvement in swollen joint count; and >= 20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]); and C-Reactive Protein (CRP)at each visit.

Eligibility Module

Eligibility Criteria

Inclusion Criteria:

Diagnosed with RA based on either the 1987-revised American College of Rheumatology (ACR) classification criteria or the 2010 ACR/European League against Rheumatism (EULAR) criteria and have an inadequate response or intolerance to methotrexate.
Subjects must have been receiving oral or parenteral methotrexate therapy ≥ 3 months and on a stable prescription of 7.5 to 25 mg/week for at least 4 weeks prior to Baseline Visit.
Have active RA as defined by the following minimum disease activity criteria:
- ≥ 6 swollen joints (based on 66 joint counts) at Screening and Baseline Visits;
- ≥ 6 tender joints (based on 68 joint counts) at Screening and Baseline Visits;
- high-sensitivity C-reactive protein (hsCRP) > upper limit of normal (ULN) OR positive for both rheumatoid factor and anti-cyclic citrullinated peptide (CCP) at Screening.
For subjects with inadequate response to methotrexate, subjects must have discontinued all oral disease-modifying anti-rheumatic drugs (DMARDs) prior to Baseline Visit as specified below or for at least five times the mean terminal elimination half-life of a drug, whichever is longer:
- ≥4 weeks prior to Baseline Visit for minocycline, penicillamine, sulfasalazine, hydroxychloroquine, chloroquine, azathioprine, gold formulations, cyclophosphamide;
- ≥12 weeks prior to Baseline Visit for leflunomide if no elimination procedure was followed, or adhere to a washout procedure (i.e., 11 days washout with colestyramine, or 30 days washout with activated charcoal).
The organ function level must meet the following requirements:

Bone marrow: Blood routine results showed hemoglobin ≥90g/L, platelet ≥100×109/L, neutrophil absolute count ≥1.5×109/L; Liver: serum bilirubin ≤1.5 times the upper limit of normal value, aspartate aminotransferase (AST) ≤1.5 times the upper limit of normal value, alanine aminotransferase (ALT) ≤1.5 times the upper limit of normal value; Serum creatinine <1.5 times the upper limit of normal value; Urine protein ≤1+, if urine protein >1+, urine protein should be collected for 24 hours, the total amount should be ≤1 g. Female subjects of childbearing potential must test negative for pregnancy.

Exclusion Criteria:

History of Felty syndrome (Rheumatoid arthritis - Splenomegaly syndrome).
A history of herpes zoster or disseminated herpes simplex.
Treatment with any JAK inhibitor (tofacitinib, baricitinib, ruxolitinib) within 2 weeks prior to study start.
Subjects have severe, progressive or uncontrollable symptoms of kidney, liver, blood, gastrointestinal, lung, cardiovascular, neurological or brain disease.
Current treatment or treatment within 4 weeks or 5 half-lives (whichever is longer) prior to the first dose of study medication with another investigational medication or current enrollment in another investigational drug protocol.
If the laboratory T-Spot test (or other TB diagnostic test) is positive, the investigator will determine the activity based on the history and clinical manifestations, and the patients diagnosed as active TB should be excluded.
Positive blood screen for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C antibody.
Pregnant or breastfeeding female.

ID	Term
D001168	Arthritis
D007592	Joint Diseases
D009140	Musculoskeletal Diseases
D012216	Rheumatic Diseases